Haemonetics acquires Vivasure Medical for up to €185M; upfront €100M plus €85M earn-out

HAEMONETICS CORP

Acquired all equity of Vivasure Medical, a Galway, Ireland-based developer of percutaneous vessel closure technology.
Upfront consideration of €100M, net €52M after deducting prior investments and loans.
Up to €85M in contingent consideration tied to sales growth and other milestones.
Transaction funded with available cash on hand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.